RPTX - Repare Therapeutics Inc.
IEX Last Trade
1.345
-1.970 -146.468%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:18:56 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$3.32
-1.97
-59.43%
Fundamental analysis
31%
Profitability
25%
Dept financing
5%
Liquidity
75%
Performance
33%
Performance
5 Days
2.27%
1 Month
-55.74%
3 Months
-60.06%
6 Months
-60.41%
1 Year
-80.29%
2 Year
-90.53%
Key data
Stock price
$1.34
DAY RANGE
$1.32 - $3.32
52 WEEK RANGE
$1.36 - $8.49
52 WEEK CHANGE
-$80.69
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Lloyd M. Segal
Region: US
Website: reparerx.com
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: reparerx.com
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach. Its lead product candidate is an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Recent news